Platelet and Red Blood Cell Aggregation

Platelet and red blood cell aggregation refers to a process in which platelets and erythrocytes clump together, primarily as part of hemostasis or pathologic thrombosis. Platelet aggregation is mediated by activation signals (including ADP, thromboxane, and collagen) and receptors (e.g., integrins, glycoproteins), while red blood cell aggregation depends on low-affinity interactions with plasma proteins, mainly fibrinogen and immunoglobulins, and is affected by membrane deformability and structure. Enhanced aggregation of either cell type can influence the local hemodynamics, tissue perfusion, and risk of vascular occlusion, and these processes are central to both physiologic clotting and various vascular diseases. Drugs that target this process usually act by inhibiting specific steps in cell activation or aggregation, rather than a single defined molecule or receptor. Key point: “Platelet and Red Blood Cell Aggregation” is not a single molecular target; it is a descriptive term for a collection of cell–cell interactions governing clot formation and blood rheology, involving several underlying molecules, cellular receptors, and membrane/cytoskeletal components.

Other names

Platelet aggregationRed blood cell aggregationPlatelet-RBC interactionsHemostatic cell aggregation

Inhibition of platelet activation and aggregation; Inhibition of fibrinogen binding (to platelets or RBCs); Modulation of ADP or thromboxane release; Alteration of cytoskeletal or membrane protein function.